

QIAGEN continues to update its range of automation solutions with the launch of high-sensitive capillary electrophoresis instrument QIAxcel Connect

- **A no-compromise solution for easier and more sensitive electrophoresis, combining power and convenience in a single high-capability instrument.**
- **Offering plug-and-play simplicity, flexible throughput and low operating costs.**
- **Integrates with the QIASphere remote-connectivity system to help increase lab productivity without increasing lab time.**

Germantown, Maryland, and Hilden, Germany, 4 May, 2022 - QIAGEN today announced the launch of QIAxcel Connect, a high-speed, high-resolution and high-sensitivity nucleic acid analysis capillary electrophoresis (CE) instrument.

Compared to other CE products on the market, QIAxcel Connect offers greater convenience due to its simple set-up, greater flexibility and low running costs. It provides high analytical power, with many applications addressed.

Until now, choosing a CE instrument has meant accepting a compromise between convenience, analytical capability and running costs. QIAxcel Connect provides labs with a powerful new all-in-one solution that combines ease of use, high capability, flexible throughput and economy in a single CE instrument.

“QIAxcel Connect combines convenience and power in one instrument,” said Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “With this launch, we further strengthen QIAGEN’s automation portfolio of high-quality products that help researchers publish their insights faster and with greater confidence.”

The enhanced platform utilizes ready-to-use gel cartridges capable of processing up to 96 samples per run and hundreds of samples before re-set up, minimizing manual intervention and reducing gel-preparation time.

The fully automated design allows for simple, flexible, and cost-effective operation while delivering maximum insight into sample quality or fragment sizes, with accurate results even at low concentration levels of DNA or RNA.

QIAxcel Connect is complemented by a wide kit portfolio with tailored capabilities to assess samples such as purified RNA, NGS libraries, cfDNA, or PCR products within minutes, at a low cost per sample.

The cartridges of these kits can be simply switched, allowing minimal handling time and offering an efficient solution for NGS Core labs and other research facilities.

By the end of the second quarter 2022, high-sensitivity kits for DNA and RNA analysis will also be available for convenient sizing and quantification in low-concentration and scarce samples.

In addition to offering high-sensitivity capabilities, QIAxcel Connect also integrates with QIASphere, a hardware-and-app system that lets users manage their instruments and receive real-time status reports even from outside the lab, thus marking another step forward in laboratory automation.



Media Release

QIASphere connectivity is also available for the syndromic testing instrument QIAstat-Dx, as well as the nucleic acid purification instruments QIAcube Connect and EZ2 Connect.

QIAxcel Connect stands in the middle of the complete QIAGEN automation workflow that includes QIAcube Connect, EZ2 Connect, QIAcube HT, or QIASymphony for sample purification, and the QIAcuity system for digital PCR.

To learn more about QIAxcel Connect, visit <http://www.qiagen.com/qiaxcel-connect>.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in molecular diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at <https://www.qiagen.com/>.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contact QIAGEN:

Public Relations
Thomas Theuringer
Tel: +49 2103 29 11826
Email: pr@QIAGEN.com